RxDoctor Payments Data

Deirdre McMullen, MD

Family Medicine · Missouri City, TXNPI 1043206733

Payments from drug & device makers

$2,323,111in general payments, 2019–2025

Across 556 payments — averaging $4178.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$860K
  • GSK$679K
  • Novartis$204K
  • Supernus Pharmaceuticals, Inc.$115K
  • Endo Pharmaceuticals Inc.$112K
  • AbbVie$76K
  • plus $279K from 52 others
$67,522in research payments, 2019–2025

Across 4 payments — averaging $16,881 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Motive Health, Inc.$67K
  • AbbVie$192

What the payments were for

  • Speaking & faculty fees$3,00041%
  • Food & beverage$4,22358%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.63$859,682
GSK76$678,701
Novartis7$203,954
Supernus Pharmaceuticals, Inc.17$114,650
Endo Pharmaceuticals Inc.28$111,748
AbbVie(2 entities)81$75,634
Evofem Biosciences, Inc.23$58,704
Taro Pharmaceuticals USA, Inc.5$46,569
Pfizer15$29,134
AstraZeneca18$22,601
Alnylam Pharmaceuticals Inc.3$21,637
Boehringer Ingelheim Canada Ltd.ltee29$20,204
Sanofi US Services Inc.1$19,550
Novo Nordisk AS7$16,153
Eli Lilly2$12,850
Boehringer Ingelheim6$10,561
Amgen(2 entities)21$8,506
Orasure Technologies Inc.2$6,594
Life Technologies Corporation2$3,000
Novo Nordisk31$546
Lilly USA, LLC24$438
Takeda Pharmaceuticals U.S.A., Inc.11$203
Teva Pharmaceuticals USA, Inc.5$133
Corium, LLC9$129
Neos Therapeutics, LP7$111
Merck7$99
Antares Pharma, Inc.5$92
Axonics, Inc.2$66
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$60
Johnson & Johnson(3 entities)4$58
Ironshore Pharmaceuticals Inc.3$57
Eisai Inc.3$54
Sanofi Pasteur Inc.3$47
Genentech USA, Inc.2$42
Tolmar, Inc.2$37
Exact Sciences2$36
Seqirus USA Inc2$33
Astellas Pharma US Inc1$33
Shire North American Group Inc2$29
Renalytix AI, Inc.1$27
Currax Pharmaceuticals LLC2$26
Bristol Myers Squibb2$26
Mission Pharmacal Company1$24
Abbott1$23
Medinc Of Texas1$21
Biohaven Pharmaceutical Holding Company Ltd.1$21
Tris Pharma Inc1$21
Azurity Pharmaceuticals, Inc.1$21
Idorsia Pharmaceuticals US Inc1$19
Halozyme Inc1$19
Amarin Pharma, Inc.1$19
Merz North America, Inc.1$18
Zyla Life Sciences, Inc.1$18
Photonicare Inc1$17
Pacira Pharmaceuticals Incorporated1$16
Collegium Pharmaceutical, Inc.1$15
Arbor Pharmaceuticals, Inc.1$14
Kowa Pharmaceuticals America, Inc.1$12

How this compares

$2,323,111 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$62,424
Medicare patients
219
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$79,879
MounjaroTirzepatide33$48,980
NucyntaTapentadol Hcl11$31,448
EliquisApixaban31$19,184
FarxigaDapagliflozin Propanediol18$11,131
LinzessLinaclotide14$7,406
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen128$4,202
Levemir FlexpenInsulin Detemir12$2,672
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,509
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$1,537
Levothyroxine Sodium153$1,498
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,189
Potassium Chloride36$1,181
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$1,176
Gabapentin74$1,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$546$79,87976 claims
Lilly USA, LLCMounjaro$438$48,98033 claims
Collegium Pharmaceutical, Inc.Nucynta$15$31,44811 claims
PfizerEliquis$29,134$19,18431 claims
AstraZenecaFarxiga$22,601$11,13118 claims
AbbVieLinzess, Synthroid$75,634$8,32525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Missouri City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →